跳至主要内容
临床试验/ACTRN12618001430224
ACTRN12618001430224已完成2 期

Efficacy of Botulinum Toxin Type A in the Targeted Treatment of Nocturnal Bruxism: A Double-Blind, Randomised, Placebo-Controlled Cross-over Study

Melbourne Health0 个研究点目标入组 41 人开始时间: 2018年8月27日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
41

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Symptoms of nocturnal bruxism of adequate severity as measured by overnight monitoring.

排除标准

  • Contraindication to botulinum toxin administration, concurrent use of medications affecting muscle relaxation, prior history of severe jaw trauma, orofacial pain of an alternate aetiology, neuromuscular disease, major respiratory disease(s) that may preclude overnight EMG recordings, administration of botulinum toxin for other indication (including cosmetic) within 16weeks of study commencement.

研究者

相似试验

Botulinum toxin for nocturnal bruxism. | 临床试验